In a patient on chronic warfarin (target INR 2.0‑3.0) scheduled for an elective percutaneous coronary intervention (PCI), what is the recommended management of warfarin, bridging anticoagulation, and antiplatelet therapy before, during, and after the procedure?

Management of Warfarin in Patients Undergoing Elective PCI

For elective PCI in patients on chronic warfarin, continue warfarin uninterrupted through the procedure without bridging anticoagulation, use radial access, load with clopidogrel 600 mg, and resume warfarin the evening of or within 24 hours post-PCI with dual therapy (warfarin + P2Y12 inhibitor) rather than triple therapy. 1

Pre-Procedural Management

Warfarin Continuation Strategy

• Continue warfarin without interruption through the elective PCI procedure 1
• Target INR should remain in therapeutic range (2.0-3.0) at time of procedure
• No bridging with heparin or LMWH is necessary for elective cases 1
  • Bridging is only considered for non-ST elevation ACS when INR is subtherapeutic and tapering off 1
  • For elective procedures, bridging increases bleeding risk without reducing thrombotic events 2

Antiplatelet Loading

• Administer aspirin 162-325 mg prior to catheterization 1
• Load with clopidogrel 600 mg in the periprocedural period 1
  • Clopidogrel is the recommended P2Y12 inhibitor (not ticagrelor or prasugrel) in anticoagulated patients 1

Procedural Considerations

Access Site Selection

• Strongly prefer radial access to minimize bleeding complications 1
  • Radial access reduces bleeding risk even when INR is therapeutic 1
  • Research confirms lower access-site complications with radial approach in anticoagulated patients 3, 2
  • Femoral access may be necessary in 5-10% of cases but increases bleeding risk 1

Intraprocedural Anticoagulation

• Use unfractionated heparin, LMWH, or bivalirudin for procedural anticoagulation 1
• All three agents have Class I recommendations; follow standard dosing guidelines 1
• Avoid glycoprotein IIb/IIIa inhibitors unless absolutely necessary (fresh thrombus, no P2Y12 pretreatment) as they significantly increase bleeding risk 1

Stent Selection

• Use newest-generation drug-eluting stents even in high bleeding risk patients 1
• Avoid bare metal stents 1

Post-Procedural Management

Warfarin Resumption Timing

• Resume warfarin the evening of PCI or within 24 hours in most patients 1
• Assess access site hemostasis before restarting 1
• Consider patient factors: recent bleeding history, body habitus (especially obese patients with femoral access), platelet abnormalities 1
• Resume the dose that previously achieved therapeutic INR 1

Post-PCI Antithrombotic Strategy

Critical Decision Point: The 2020 ACC Expert Consensus strongly recommends switching to a DOAC post-PCI rather than continuing warfarin 1. However, if continuing warfarin:

Default Strategy: Dual Therapy (Preferred)

• Warfarin + P2Y12 inhibitor (clopidogrel) WITHOUT aspirin 1
• This is the standard approach to minimize bleeding while maintaining efficacy
• Target INR 2.0-2.5 (lower end of therapeutic range) 1

Bridging Strategy (Very Limited Use)

• Only for patients with very high thromboembolic risk (e.g., mechanical valve, recent VTE) 1
• Use parenteral anticoagulation only until INR reaches therapeutic range
• Most patients should NOT receive bridging post-PCI 1

For Patients NOT Bridged Post-PCI

• Continue low-dose aspirin (81 mg) + P2Y12 inhibitor + warfarin until INR is therapeutic 1
• Once INR is at goal, stop aspirin immediately and continue dual therapy (warfarin + clopidogrel) 1

Triple Therapy Consideration (Exceptional Cases Only)

• May consider aspirin 81 mg daily for up to 30 days only in patients with:
  • High thrombotic risk (complex PCI, bifurcation lesions, long stents, thrombus-containing lesions) 1
  • AND low bleeding risk 1
• After 30 days maximum, stop aspirin and continue dual therapy 1

Duration of Dual Therapy

• Minimum 6 months for acute coronary syndrome presentation 1
• Minimum 3 months for stable ischemic heart disease 1
• After this period, can consider stopping P2Y12 inhibitor and continuing warfarin monotherapy in high bleeding risk patients 1

Bleeding Risk Mitigation

Mandatory Measures

• Start proton pump inhibitor (or H2-receptor antagonist) for all patients on ≥2 antithrombotic agents 1
• Discontinue PPI when returning to anticoagulation monotherapy unless other indication exists 1
• Avoid NSAIDs completely 1
• Omeprazole concerns with clopidogrel are outweighed by GI bleeding protection 1

INR Monitoring

• More frequent INR monitoring when on multiple antithrombotic agents 1
• Aim for time in therapeutic range >70% 4
• Check INR before discharge and within 3-5 days post-PCI

Common Pitfalls to Avoid

1. Do not routinely bridge with LMWH for elective PCI—this increases bleeding without reducing thrombotic events 1, 2
2. Do not use triple therapy as default—dual therapy (warfarin + P2Y12 inhibitor) is preferred 1
3. Do not use femoral access routinely—radial access significantly reduces bleeding 1, 2
4. Do not continue aspirin long-term—stop after INR is therapeutic or maximum 30 days 1
5. Do not use prasugrel or ticagrelor—clopidogrel is the recommended P2Y12 inhibitor 1

Key Evidence Nuances

The evidence strongly supports uninterrupted warfarin for elective PCI. Research demonstrates that continuing warfarin (with therapeutic INR 2.2-2.3) results in lower bleeding rates than interrupting warfarin (INR 1.5-1.7) with or without bridging 3, 5. The WAR-STENT registry showed similar efficacy and safety between continuation versus interruption strategies, with continuation being more convenient 6. Most recent data from the PERSEO registry confirms that bridging therapy independently predicts bleeding complications (OR 2.39) 2.

The shift away from triple therapy is supported by multiple trials (PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, ENTRUST-AF PCI) showing dual therapy reduces bleeding without increasing ischemic events 1.